Jason Ruth

Partner, MRL Ventures Fund

2022

- Led investments in Series As for Aktis Oncology, Ray Therapeutics. - Board Observer roles with Aktis Oncology, Ray Therapeutics, LifeMine Therapeutics.

Principal

2020 - 2022

Public and crossover investing: - Established and co-led 5AM's late-stage fund for crossover and public investments. Investments included Prometheus Biosciences (acquired for $10.8b), Iveric Bio (acquired for $5.9b), Disc Medicine (NASDAQ: IRON), Janux Therapeutics (NASDAQ: JANX), and others.

Senior Associate

2019 - 2020

Venture capital and venture creation: - Cabaletta Bio (NASDAQ: CABA): Led Series A investment, Board Observer. - Entrada Therapeutics (NASDAQ: TRDA): Co-led Seed and Series A investments, co-inventor on patent and company building through part-time operational role, Board Observer. - Vor Biopharma (NASDAQ: VOR): Co-led Series A investment, company building through part-time operational role, Board Observer. - Supported existing investment in Expansion Therapeutics, Board Observer role.

Associate

2017 - 2018

Board Observer

2017 - 2021

- 5AM founded Expansion Therapeutics and led the $55M Series A investment. - Expansion Therapeutics, founded by 5AM Ventures and Matt Disney from The Scripps Research Institute, is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Board Observer

2017 - 2021

- Previously a Board Observer for Entrada Therapeutics (NASDAQ: TRDA). - Interim operations role during seed, co-inventor on patent. - 5AM founded Entrada Therapeutics and led the $59M Series A investment. - Entrada Therapeutics, founded by 5AM Ventures and Dehua Pei from OSU, is a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics.

Board Observer

2019 - 2021

- Previously a Board Observer with Vor Biopharma (NASDAQ:VOR). - 5AM led $42M Series A investment. - Vor Biopharma is an immuno-oncology company developing edited stem cell therapies that can enable selective targeting of cancer cells without impacting normal cells.

Board Observer

2018 - 2019

- Previously a Board Observer with Cabaletta Bio (NASDAQ:CABA). - 5AM led $38M Series A and participated in $50M Series B investments. - Cabaletta is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases.

Board Observer

2017 - 2018

- Previously a Board Observer with Homology Medicines (NASDAQ:FIXX). - Homology Medicines, founded by 5AM Ventures and Saswati Chatterjee from City of Hope, is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Postdoctoral Research Fellow

2014 - 2016

Postdoctoral Research Fellow

2014 - 2016

Postdoctoral Research Fellow in Levi Garraway's laboratory - Co-first author publication in Science: Discovered mechanistic basis for PRMT5 depenedency in MTAP null cancers, providing the initial rationale for development of MTA-cooperative PRMT5 inhibitors. - Co-inventor on patent for "Selective treatment of prmt5 dependent cancer" - Started course in Biomedical Entrepreneurship at the Broad Institute, where Industry experts teach Broad Institute and MIT researchers the basics of biotech and research commercialization, participants develop and pitch plans to commercialize their work.

PhD in Bioengineering

2008 - 2014

PhD in Bioengineering from Lewis Chodosh's Laboratory, Dept. Cancer Biology - Coursework: Medical school curriculum plus graduate bioengineering courses. - HHMI-NIBIB Interfaces Fellowship, 1 of 3 PhD students awarded at UPenn in 2008. - NCI F31 Kirschstein Predoctoral Fellowship to investigate cancer immunology. - Awarded Best Presentation at 2014 Department of Cancer Biology Annual Retreat. - Mentored 5 researchers: 1 visiting PhD, 3 PhD rotation students, 1 undergraduate.